论文部分内容阅读
目的研究重组人内皮抑素对荷人肺腺癌裸鼠肿瘤微环境的调节作用。方法构建人肺腺癌裸鼠模型,重组人内皮抑素5mg/kg皮下给药14天。采用荧光素(TRlTC-Dex-tran)示踪法,荧光显微镜观察重组人内皮抑素处理后不同时间点荧光素在肿瘤中的分布,并计算肿瘤实质内部荧光素不能弥散到的面积相对于总面积的比例。结果给予处理14天后,对照组肿瘤内部血液弥散减少(低弥散面积占总面积的10.01%±4.50%),相对于第7和第21天显著增高(分别为1.49%±1.14%和2.90%±2.02%)。重组人内皮抑素能够在治疗的初始阶段抑制血液的弥散(低弥散面积占总面积的16.85%±4.03%),但第14天后这种抑制作用解除,肿瘤内部血液弥散反而增加(0.54%±0.32%,P=0.000),到第21天时则两组没有明显差别。讨论重组人血管内皮抑素能够暂时性的抑制肿瘤血管,此外重组人内皮抑素还能够调节肿瘤的内环境,在一段时间内增加了肿瘤内部血液弥散。
Objective To study the regulatory effect of recombinant human endostatin on the tumor microenvironment of nude mice bearing human lung adenocarcinoma. Methods Human lung adenocarcinoma xenograft model was established. Human recombinant human endostatin 5 mg / kg was administered subcutaneously for 14 days. Fluorescein (TRlTC-Dex-tran) tracer method was used to observe the distribution of fluorescein in the tumor at different time points after treatment with recombinant human endostatin by fluorescence microscopy, and the area that can not diffuse into the tumor parenchyma with respect to the total Area ratio. Results After 14 days of treatment, there was a decrease in blood flow within the tumor in the control group (low dispersive area of 10.01% ± 4.50% of the total area) and a significant increase from days 7 and 21 (1.49% ± 1.14% and 2.90% ± 2.02%). Recombinant human endostatin can inhibit the blood dispersion in the initial stage of treatment (low dispersion area accounted for 16.85% ± 4.03% of the total area), but after 14 days, this inhibition was relieved, but the blood circulation within the tumor increased instead (0.54% ± 0.32%, P = 0.000). There was no significant difference between the two groups by day 21. Discussion Recombinant human endostatin can temporarily inhibit the tumor blood vessels, in addition recombinant human endostatin can also regulate the tumor’s internal environment, increased blood flow within the tumor for a period of time.